Ajovy is under development in Japan by Otsuka as part of a May 2017 exclusive license agreement for development and sales of Ajovy in Japan.
Earlier this year, the two companies announced outcomes from two pivotal studies of Ajovy in Japan in patients with episodic and chronic migraine. The primary endpoints were achieved in both trials with clinical and statistical significance versus placebo. Statistically significant improvements versus placebo also were demonstrated for all secondary endpoints.
Ajovy was well tolerated with a similar adverse events profile compared to placebo.
Ajovy is the first and only long-acting anti-CGRP subcutaneous injection approved in the US and EU that is designed for the preventive treatment of migraine and offers both quarterly and monthly dosing options.
Teva Pharmaceutical Industries is in generic and specialty medicines, with a portfolio consisting of over 3,500 products in nearly every therapeutic area.
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling